Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Killestein

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Neurology|April 4, 2000
MS functional composite: relation to disease phenotype and disability strataN F Kalkers, V de Groot, R H Lazeron, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 26, 2021
Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosisK H Lam, P van Oirschot, B den Teuling, et al.
Journal of Neuroimmunology|November 26, 2002
Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-betaJ Killestein, R Q Hintzen, B M J Uitdehaag, et al.
Journal of Neuroimmunology|November 6, 2001
Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosisA H van Boxel-Dezaire, M Smits, S C van Trigt-Hoff, et al.
Journal of Neuroimmunology|August 4, 2012
Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosisP Tewarie, C E Teunissen, C D Dijkstra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 15, 2012
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progressionC E Teunissen, M Sombekke, L van Winsen, et al.
Neurology|February 9, 2011
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MSA Vennegoor, M P Wattjes, E T L van Munster, et al.
Multiple Sclerosis and Related Disorders|May 14, 2021
Natalizumab discontinuation in a Dutch real-world cohortE M E Coerver, M H J Wessels, Z Y G van Lierop, et al.
Annals of Neurology|September 8, 2000
Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?A H van Boxel-Dezaire, S C van Trigt-Hoff, J Killestein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practiceL F van der Voort, A Kok, A Visser, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Neurology|April 4, 2000
MS functional composite: relation to disease phenotype and disability strataN F Kalkers, V de Groot, R H Lazeron, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 26, 2021
Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosisK H Lam, P van Oirschot, B den Teuling, et al.
Journal of Neuroimmunology|November 26, 2002
Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-betaJ Killestein, R Q Hintzen, B M J Uitdehaag, et al.
Journal of Neuroimmunology|November 6, 2001
Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosisA H van Boxel-Dezaire, M Smits, S C van Trigt-Hoff, et al.
Journal of Neuroimmunology|August 4, 2012
Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosisP Tewarie, C E Teunissen, C D Dijkstra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 15, 2012
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progressionC E Teunissen, M Sombekke, L van Winsen, et al.
Neurology|February 9, 2011
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MSA Vennegoor, M P Wattjes, E T L van Munster, et al.
Multiple Sclerosis and Related Disorders|May 14, 2021
Natalizumab discontinuation in a Dutch real-world cohortE M E Coerver, M H J Wessels, Z Y G van Lierop, et al.
Annals of Neurology|September 8, 2000
Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?A H van Boxel-Dezaire, S C van Trigt-Hoff, J Killestein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practiceL F van der Voort, A Kok, A Visser, et al.
Pageof 9